

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Growth 2023-2029

<https://marketpublishers.com/r/GC281089EBAFEN.html>

Date: March 2023

Pages: 108

Price: US\$ 3,660.00 (Single User License)

ID: GC281089EBAFEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

An angiotensin-converting-enzyme inhibitor (ACE inhibitor) is a pharmaceutical drug used primarily for the treatment of hypertension (elevated blood pressure) and congestive heart failure.

LPI (LP Information)' newest research report, the “Angiotensin Converting Enzyme (ACE) Inhibitors Industry Forecast” looks at past sales and reviews total world Angiotensin Converting Enzyme (ACE) Inhibitors sales in 2022, providing a comprehensive analysis by region and market sector of projected Angiotensin Converting Enzyme (ACE) Inhibitors sales for 2023 through 2029. With Angiotensin Converting Enzyme (ACE) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Angiotensin Converting Enzyme (ACE) Inhibitors industry.

This Insight Report provides a comprehensive analysis of the global Angiotensin Converting Enzyme (ACE) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Angiotensin Converting Enzyme (ACE) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Angiotensin Converting Enzyme (ACE) Inhibitors market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Angiotensin Converting Enzyme (ACE) Inhibitors and

breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Angiotensin Converting Enzyme (ACE) Inhibitors.

The global Angiotensin Converting Enzyme (ACE) Inhibitors market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Angiotensin Converting Enzyme (ACE) Inhibitors is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Angiotensin Converting Enzyme (ACE) Inhibitors is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Angiotensin Converting Enzyme (ACE) Inhibitors is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Angiotensin Converting Enzyme (ACE) Inhibitors players cover Abbott Laboratories, Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi and Bristol-Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Angiotensin Converting Enzyme (ACE) Inhibitors market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Sulfhydryl-containing Agents

Dicarboxylate-containing Agents

Phosphonate-containing Agents

Segmentation by application

Hypertension

Cardiovascular Diseases

Kidney Diseases

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Abbott Laboratories

Pfizer

Novartis

Merck

Astra Zeneca

Jhonson and Johnson

Eli Lilly

Sanofi

Bristol-Myers Squibb

Bayer

GSK

Teva Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Angiotensin Converting Enzyme (ACE) Inhibitors market?

What factors are driving Angiotensin Converting Enzyme (ACE) Inhibitors market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Angiotensin Converting Enzyme (ACE) Inhibitors market opportunities vary by end market size?

How does Angiotensin Converting Enzyme (ACE) Inhibitors break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales 2018-2029

2.1.2 World Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region, 2018, 2022 & 2029

2.1.3 World Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Country/Region, 2018, 2022 & 2029

2.2 Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Type

2.2.1 Sulfhydryl-containing Agents

2.2.2 Dicarboxylate-containing Agents

2.2.3 Phosphonate-containing Agents

2.3 Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type

2.3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2018-2023)

2.3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue and Market Share by Type (2018-2023)

2.3.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Type (2018-2023)

2.4 Angiotensin Converting Enzyme (ACE) Inhibitors Segment by Application

2.4.1 Hypertension

2.4.2 Cardiovascular Diseases

2.4.3 Kidney Diseases

2.4.4 Other

2.5 Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application

2.5.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Market Share by Application (2018-2023)

2.5.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue and Market Share by Application (2018-2023)

2.5.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Application (2018-2023)

3 GLOBAL ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS BY COMPANY

3.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Breakdown Data by Company

3.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales by Company (2018-2023)

3.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Company (2018-2023)

3.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Revenue by Company (2018-2023)

3.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Company (2018-2023)

3.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Company (2018-2023)

3.3 Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Company

3.4 Key Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Product Location Distribution

3.4.2 Players Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS BY GEOGRAPHIC REGION

4.1 World Historic Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Geographic Region (2018-2023)

- 4.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales by Geographic Region (2018-2023)
- 4.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Revenue by Geographic Region (2018-2023)
- 4.2 World Historic Angiotensin Converting Enzyme (ACE) Inhibitors Market Size by Country/Region (2018-2023)
 - 4.2.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales by Country/Region (2018-2023)
 - 4.2.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Revenue by Country/Region (2018-2023)
- 4.3 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth
- 4.4 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth
- 4.5 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth
- 4.6 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth

5 AMERICAS

- 5.1 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country
 - 5.1.1 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2018-2023)
 - 5.1.2 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2018-2023)
- 5.2 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type
- 5.3 Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region
 - 6.1.1 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2018-2023)
 - 6.1.2 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2018-2023)
- 6.2 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type
- 6.3 APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application
- 6.4 China

- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors by Country
 - 7.1.1 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2018-2023)
 - 7.1.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2018-2023)
- 7.2 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type
- 7.3 Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors by Country
 - 8.1.1 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2018-2023)
 - 8.1.2 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2018-2023)
- 8.2 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type
- 8.3 Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors

10.3 Manufacturing Process Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors

10.4 Industry Chain Structure of Angiotensin Converting Enzyme (ACE) Inhibitors

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Angiotensin Converting Enzyme (ACE) Inhibitors Distributors

11.3 Angiotensin Converting Enzyme (ACE) Inhibitors Customer

12 WORLD FORECAST REVIEW FOR ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS BY GEOGRAPHIC REGION

12.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Size Forecast by Region

12.1.1 Global Angiotensin Converting Enzyme (ACE) Inhibitors Forecast by Region (2024-2029)

12.1.2 Global Angiotensin Converting Enzyme (ACE) Inhibitors Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Angiotensin Converting Enzyme (ACE) Inhibitors Forecast by Type

12.7 Global Angiotensin Converting Enzyme (ACE) Inhibitors Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Abbott Laboratories

13.1.1 Abbott Laboratories Company Information

13.1.2 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.1.3 Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.1.4 Abbott Laboratories Main Business Overview

13.1.5 Abbott Laboratories Latest Developments

13.2 Pfizer

13.2.1 Pfizer Company Information

13.2.2 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.2.3 Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Pfizer Main Business Overview

13.2.5 Pfizer Latest Developments

13.3 Novartis

13.3.1 Novartis Company Information

13.3.2 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.3.3 Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Novartis Main Business Overview

13.3.5 Novartis Latest Developments

13.4 Merck

13.4.1 Merck Company Information

13.4.2 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.4.3 Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Merck Main Business Overview

13.4.5 Merck Latest Developments

13.5 Astra Zeneca

13.5.1 Astra Zeneca Company Information

13.5.2 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.5.3 Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales,

Revenue, Price and Gross Margin (2018-2023)

13.5.4 Astra Zeneca Main Business Overview

13.5.5 Astra Zeneca Latest Developments

13.6 Jhonson and Johnson

13.6.1 Jhonson and Johnson Company Information

13.6.2 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.6.3 Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Jhonson and Johnson Main Business Overview

13.6.5 Jhonson and Johnson Latest Developments

13.7 Eli Lilly

13.7.1 Eli Lilly Company Information

13.7.2 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.7.3 Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Eli Lilly Main Business Overview

13.7.5 Eli Lilly Latest Developments

13.8 Sanofi

13.8.1 Sanofi Company Information

13.8.2 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.8.3 Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 Sanofi Main Business Overview

13.8.5 Sanofi Latest Developments

13.9 Bristol-Myers Squibb

13.9.1 Bristol-Myers Squibb Company Information

13.9.2 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.9.3 Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 Bristol-Myers Squibb Main Business Overview

13.9.5 Bristol-Myers Squibb Latest Developments

13.10 Bayer

13.10.1 Bayer Company Information

13.10.2 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.10.3 Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Bayer Main Business Overview

13.10.5 Bayer Latest Developments

13.11 GSK

13.11.1 GSK Company Information

13.11.2 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.11.3 GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 GSK Main Business Overview

13.11.5 GSK Latest Developments

13.12 Teva Pharmaceutical

13.12.1 Teva Pharmaceutical Company Information

13.12.2 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

13.12.3 Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 Teva Pharmaceutical Main Business Overview

13.12.5 Teva Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Angiotensin Converting Enzyme (ACE) Inhibitors Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of Sulfhydryl-containing Agents
- Table 4. Major Players of Dicarboxylate-containing Agents
- Table 5. Major Players of Phosphonate-containing Agents
- Table 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2018-2023) & (K MT)
- Table 7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2018-2023)
- Table 8. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Type (2018-2023) & (\$ million)
- Table 9. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2018-2023)
- Table 10. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Type (2018-2023) & (USD/MT)
- Table 11. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2018-2023) & (K MT)
- Table 12. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2018-2023)
- Table 13. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Application (2018-2023)
- Table 14. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Application (2018-2023)
- Table 15. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Application (2018-2023) & (USD/MT)
- Table 16. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Company (2018-2023) & (K MT)
- Table 17. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Company (2018-2023)
- Table 18. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Company (2018-2023) (\$ Millions)
- Table 19. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Company (2018-2023)

Table 20. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sale Price by Company (2018-2023) & (USD/MT)

Table 21. Key Manufacturers Angiotensin Converting Enzyme (ACE) Inhibitors Producing Area Distribution and Sales Area

Table 22. Players Angiotensin Converting Enzyme (ACE) Inhibitors Products Offered

Table 23. Angiotensin Converting Enzyme (ACE) Inhibitors Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 24. New Products and Potential Entrants

Table 25. Mergers & Acquisitions, Expansion

Table 26. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Geographic Region (2018-2023) & (K MT)

Table 27. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share Geographic Region (2018-2023)

Table 28. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 29. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Geographic Region (2018-2023)

Table 30. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country/Region (2018-2023) & (K MT)

Table 31. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country/Region (2018-2023)

Table 32. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country/Region (2018-2023) & (\$ millions)

Table 33. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country/Region (2018-2023)

Table 34. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2018-2023) & (K MT)

Table 35. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2018-2023)

Table 36. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2018-2023) & (\$ Millions)

Table 37. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2018-2023)

Table 38. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2018-2023) & (K MT)

Table 39. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2018-2023) & (K MT)

Table 40. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2018-2023) & (K MT)

Table 41. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region (2018-2023)

Table 42. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Region (2018-2023) & (\$ Millions)

Table 43. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Region (2018-2023)

Table 44. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2018-2023) & (K MT)

Table 45. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2018-2023) & (K MT)

Table 46. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2018-2023) & (K MT)

Table 47. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2018-2023)

Table 48. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2018-2023) & (\$ Millions)

Table 49. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2018-2023)

Table 50. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2018-2023) & (K MT)

Table 51. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2018-2023) & (K MT)

Table 52. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Country (2018-2023) & (K MT)

Table 53. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country (2018-2023)

Table 54. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue by Country (2018-2023) & (\$ Millions)

Table 55. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country (2018-2023)

Table 56. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Type (2018-2023) & (K MT)

Table 57. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Application (2018-2023) & (K MT)

Table 58. Key Market Drivers & Growth Opportunities of Angiotensin Converting Enzyme (ACE) Inhibitors

Table 59. Key Market Challenges & Risks of Angiotensin Converting Enzyme (ACE) Inhibitors

Table 60. Key Industry Trends of Angiotensin Converting Enzyme (ACE) Inhibitors

- Table 61. Angiotensin Converting Enzyme (ACE) Inhibitors Raw Material
- Table 62. Key Suppliers of Raw Materials
- Table 63. Angiotensin Converting Enzyme (ACE) Inhibitors Distributors List
- Table 64. Angiotensin Converting Enzyme (ACE) Inhibitors Customer List
- Table 65. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Region (2024-2029) & (K MT)
- Table 66. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 67. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Country (2024-2029) & (K MT)
- Table 68. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 69. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Region (2024-2029) & (K MT)
- Table 70. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 71. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Country (2024-2029) & (K MT)
- Table 72. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 73. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Country (2024-2029) & (K MT)
- Table 74. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 75. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Type (2024-2029) & (K MT)
- Table 76. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Type (2024-2029) & (\$ Millions)
- Table 77. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Forecast by Application (2024-2029) & (K MT)
- Table 78. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Forecast by Application (2024-2029) & (\$ Millions)
- Table 79. Abbott Laboratories Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors
- Table 80. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications
- Table 81. Abbott Laboratories Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)
- Table 82. Abbott Laboratories Main Business

Table 83. Abbott Laboratories Latest Developments

Table 84. Pfizer Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 85. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 86. Pfizer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 87. Pfizer Main Business

Table 88. Pfizer Latest Developments

Table 89. Novartis Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 90. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 91. Novartis Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 92. Novartis Main Business

Table 93. Novartis Latest Developments

Table 94. Merck Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 95. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 96. Merck Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 97. Merck Main Business

Table 98. Merck Latest Developments

Table 99. Astra Zeneca Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 100. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 101. Astra Zeneca Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 102. Astra Zeneca Main Business

Table 103. Astra Zeneca Latest Developments

Table 104. Jhonson and Johnson Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 105. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 106. Jhonson and Johnson Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 107. Jhonson and Johnson Main Business

Table 108. Jhonson and Johnson Latest Developments

Table 109. Eli Lilly Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 110. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 111. Eli Lilly Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 112. Eli Lilly Main Business

Table 113. Eli Lilly Latest Developments

Table 114. Sanofi Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 115. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 116. Sanofi Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 117. Sanofi Main Business

Table 118. Sanofi Latest Developments

Table 119. Bristol-Myers Squibb Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 120. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 121. Bristol-Myers Squibb Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 122. Bristol-Myers Squibb Main Business

Table 123. Bristol-Myers Squibb Latest Developments

Table 124. Bayer Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 125. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 126. Bayer Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 127. Bayer Main Business

Table 128. Bayer Latest Developments

Table 129. GSK Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 130. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 131. GSK Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT),

Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 132. GSK Main Business

Table 133. GSK Latest Developments

Table 134. Teva Pharmaceutical Basic Information, Angiotensin Converting Enzyme (ACE) Inhibitors Manufacturing Base, Sales Area and Its Competitors

Table 135. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Product Portfolios and Specifications

Table 136. Teva Pharmaceutical Angiotensin Converting Enzyme (ACE) Inhibitors Sales (K MT), Revenue (\$ Million), Price (USD/MT) and Gross Margin (2018-2023)

Table 137. Teva Pharmaceutical Main Business

Table 138. Teva Pharmaceutical Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Angiotensin Converting Enzyme (ACE) Inhibitors
- Figure 2. Angiotensin Converting Enzyme (ACE) Inhibitors Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Growth Rate 2018-2029 (K MT)
- Figure 7. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Angiotensin Converting Enzyme (ACE) Inhibitors Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Sulfhydryl-containing Agents
- Figure 10. Product Picture of Dicarboxylate-containing Agents
- Figure 11. Product Picture of Phosphonate-containing Agents
- Figure 12. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type in 2022
- Figure 13. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Type (2018-2023)
- Figure 14. Angiotensin Converting Enzyme (ACE) Inhibitors Consumed in Hypertension
- Figure 15. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Hypertension (2018-2023) & (K MT)
- Figure 16. Angiotensin Converting Enzyme (ACE) Inhibitors Consumed in Cardiovascular Diseases
- Figure 17. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Cardiovascular Diseases (2018-2023) & (K MT)
- Figure 18. Angiotensin Converting Enzyme (ACE) Inhibitors Consumed in Kidney Diseases
- Figure 19. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Kidney Diseases (2018-2023) & (K MT)
- Figure 20. Angiotensin Converting Enzyme (ACE) Inhibitors Consumed in Other
- Figure 21. Global Angiotensin Converting Enzyme (ACE) Inhibitors Market: Other (2018-2023) & (K MT)
- Figure 22. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2022)
- Figure 23. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market

Share by Application in 2022

Figure 24. Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market by Company in 2022 (K MT)

Figure 25. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Company in 2022

Figure 26. Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market by Company in 2022 (\$ Million)

Figure 27. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Company in 2022

Figure 28. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Geographic Region (2018-2023)

Figure 29. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Geographic Region in 2022

Figure 30. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2018-2023 (K MT)

Figure 31. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2018-2023 (\$ Millions)

Figure 32. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2018-2023 (K MT)

Figure 33. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2018-2023 (\$ Millions)

Figure 34. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2018-2023 (K MT)

Figure 35. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2018-2023 (\$ Millions)

Figure 36. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales 2018-2023 (K MT)

Figure 37. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue 2018-2023 (\$ Millions)

Figure 38. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country in 2022

Figure 39. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country in 2022

Figure 40. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2018-2023)

Figure 41. Americas Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2018-2023)

Figure 42. United States Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Canada Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 44. Mexico Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 45. Brazil Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 46. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Region in 2022

Figure 47. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Regions in 2022

Figure 48. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2018-2023)

Figure 49. APAC Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2018-2023)

Figure 50. China Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Japan Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 52. South Korea Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Southeast Asia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 54. India Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Australia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 56. China Taiwan Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 57. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country in 2022

Figure 58. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country in 2022

Figure 59. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2018-2023)

Figure 60. Europe Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2018-2023)

Figure 61. Germany Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 62. France Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth

2018-2023 (\$ Millions)

Figure 63. UK Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth

2018-2023 (\$ Millions)

Figure 64. Italy Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth

2018-2023 (\$ Millions)

Figure 65. Russia Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth

2018-2023 (\$ Millions)

Figure 66. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Country in 2022

Figure 67. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share by Country in 2022

Figure 68. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Type (2018-2023)

Figure 69. Middle East & Africa Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share by Application (2018-2023)

Figure 70. Egypt Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 71. South Africa Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Israel Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Turkey Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 74. GCC Country Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Growth 2018-2023 (\$ Millions)

Figure 75. Manufacturing Cost Structure Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors in 2022

Figure 76. Manufacturing Process Analysis of Angiotensin Converting Enzyme (ACE) Inhibitors

Figure 77. Industry Chain Structure of Angiotensin Converting Enzyme (ACE) Inhibitors

Figure 78. Channels of Distribution

Figure 79. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Forecast by Region (2024-2029)

Figure 80. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share Forecast by Region (2024-2029)

Figure 81. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share Forecast by Type (2024-2029)

Figure 82. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share Forecast by Type (2024-2029)

Figure 83. Global Angiotensin Converting Enzyme (ACE) Inhibitors Sales Market Share Forecast by Application (2024-2029)

Figure 84. Global Angiotensin Converting Enzyme (ACE) Inhibitors Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Angiotensin Converting Enzyme (ACE) Inhibitors Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GC281089EBAFEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GC281089EBAFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970